Phaseline

Companies › X4 Pharmaceuticals

X4 Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mavorixafor
C-X-C chemokine receptor type 4 antagonist
CXCR4Phase 3NeutropeniaSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06056297MavorixaforPhase 3NeutropeniaHematologySep 2027

From the company's SEC filings

Cash and short-term investments of $188m on 2026-09-30; operating cash outflow about $81m a year; runway about 28 months at that burn, to Jan 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

CXCR4 (1)

Companies with the same targets

Guangzhou Gloria Biosciences BioLineRx

Companies built like this

Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Forma Therapeutics Wuhan Createrna Science and Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.